Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. cut its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 5.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 126,375 shares of the life sciences company's stock after selling 7,719 shares during the quarter. Victory Capital Management Inc. owned 0.08% of Illumina worth $16,481,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Janney Montgomery Scott LLC increased its stake in shares of Illumina by 41.5% in the 1st quarter. Janney Montgomery Scott LLC now owns 3,070 shares of the life sciences company's stock worth $422,000 after purchasing an additional 900 shares in the last quarter. Orion Portfolio Solutions LLC increased its stake in shares of Illumina by 10.4% in the 1st quarter. Orion Portfolio Solutions LLC now owns 7,918 shares of the life sciences company's stock worth $1,087,000 after purchasing an additional 746 shares in the last quarter. Edgestream Partners L.P. purchased a new stake in Illumina in the 1st quarter worth $384,000. O Shaughnessy Asset Management LLC increased its stake in Illumina by 91.7% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 4,199 shares of the life sciences company's stock worth $577,000 after buying an additional 2,009 shares in the last quarter. Finally, UniSuper Management Pty Ltd increased its stake in Illumina by 392.7% in the 1st quarter. UniSuper Management Pty Ltd now owns 8,810 shares of the life sciences company's stock worth $1,210,000 after buying an additional 7,022 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Stock Down 2.5 %

Shares of NASDAQ:ILMN traded down $3.32 during trading hours on Wednesday, reaching $131.68. The stock had a trading volume of 3,065,218 shares, compared to its average volume of 2,031,821. Illumina, Inc. has a 1 year low of $93.51 and a 1 year high of $156.66. The firm's 50 day moving average is $140.04 and its 200-day moving average is $124.47. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The stock has a market capitalization of $20.88 billion, a price-to-earnings ratio of -13.55 and a beta of 1.13.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating analysts' consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company's revenue was down 3.5% on a year-over-year basis. During the same period last year, the firm posted $0.33 EPS. Research analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ILMN. Royal Bank of Canada increased their price target on Illumina from $252.00 to $254.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 5th. TD Cowen increased their price objective on shares of Illumina from $166.00 to $177.00 and gave the company a "buy" rating in a report on Tuesday, November 5th. Leerink Partners increased their price objective on shares of Illumina from $160.00 to $200.00 and gave the company an "outperform" rating in a report on Thursday, October 17th. Daiwa Capital Markets raised shares of Illumina from a "neutral" rating to a "buy" rating and increased their price objective for the company from $120.00 to $154.00 in a report on Friday, August 16th. Finally, HSBC raised shares of Illumina from a "hold" rating to a "buy" rating and set a $180.00 price objective for the company in a report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $164.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.